Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 10.3657 million shares, which represents no more than 1% of the company's total share capital [1] Summary by Relevant Sections - Shareholding Reduction Plan - Mr. Yang Zongmeng intends to reduce his holdings through centralized bidding within three months after a 15 trading day period from the announcement date [1] - The maximum number of shares to be sold is 10.3657 million [1] - The planned reduction will not exceed 1% of the total share capital of the company [1]

Core Viewpoint - Fudan Zhangjiang announced that shareholder Yang Zongmeng, holding 64.0098 million shares (6.18% of total shares), plans to reduce his holdings by up to 10.3657 million shares (not exceeding 1.00% of total shares) within three months starting from November 26, 2025, to February 25, 2026, at a price not lower than 8.64 yuan per share after adjustment for ex-rights and ex-dividends [1] Summary by Sections - Shareholder Information - Yang Zongmeng holds 64.0098 million shares, representing 6.18% of the total shares [1] - Reduction Plan - The planned reduction is up to 10.3657 million shares, which is a maximum of 1.00% of total shares [1] - The reduction period is set from November 26, 2025, to February 25, 2026 [1] - Pricing Details - The minimum selling price for the reduced shares is set at 8.64 yuan per share, adjusted for ex-rights and ex-dividends [1]

Core Viewpoint - Fudan Zhangjiang (01349) announced that shareholder Yang Zongmeng plans to reduce his stake in the company due to personal funding needs, intending to sell up to 10,365,721 shares, which represents a maximum of 1.00% of the company's total share capital [1] Summary by Relevant Sections - Shareholder Action - Yang Zongmeng has issued a notice regarding his plan to reduce his holdings in Fudan Zhangjiang [1] - The reduction will occur through centralized bidding within three months after a 15 trading day period following the announcement [1] - Share Reduction Details - The maximum number of shares to be sold is 10,365,721 [1] - This reduction accounts for no more than 1.00% of the total share capital of the company [1]

Group 1 - The core point of the article is that Fudan Zhangjiang (01349) has received a notice from shareholder Yang Zongmeng regarding a plan to reduce his shareholding in the company due to personal funding needs [1] - Yang Zongmeng plans to reduce his holdings by no more than 10,365,721 shares, which represents up to 1.00% of the company's total share capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份計劃公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 二零二五年十一月四日 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 *僅供識別 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先 ...

此乃要件 請即處理 閣下對本通函的任何內容或將採取的行動如有任何疑問，應諮詢 閣下的股票經紀或其他註冊 證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下的上海復旦張江生物醫藥股份有限公司股份，應立即將本通函及 隨附委任代理表格送交買主或承讓人或經手買賣的銀行、股票經紀或其他代理商，以便轉交買 主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就本通函全部或任何部分內容而產生的或因依 賴該等內容而引致的任何損失承擔任何責任。 上海復旦張江生物醫藥股份有限公司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股票號碼：1349） 審議：(1)變更A股首次公開發行股票所得款項用途；及 (2)建議修訂公司章程及其他制度及取消監事會 董事會函件載於本通函第3頁至第15頁。 本公司謹訂於二零二五年十一月二十六日（星期三）下午十三時正假座中國上海市浦東新區張江 高科技園區蔡倫路308號舉行臨時 ...

或委任大會主席代表本人╱吾等出席於二零二五年十一月二十六日（星期三）下午十三時正假座中國上海市浦東新區張江高科 技園區蔡倫路308號舉行的臨時股東大會（「大會」或「臨時股東大會」）或其任何續會，並依照下列指示代表本人╱吾等就本公 司日期為二零二五年十一月四日的臨時股東大會通告（「通告」）所列的決議案投票。如無作出指示，則由本人╱吾等的委託代 理人自行酌情投贊成票或反對票。 除文義另有所指外，本委託代理人表格及下列決議案所使用的詞滙與本公司日期為二零二五年十一月四日的臨時股東大會通 函（「通函」）所界定者具有相同涵義。 | | 普通決議案 | （註4） 贊成 | （註4） 反對 | （註4） 棄權 | | --- | --- | --- | --- | --- | | 1. | 審議及批准變更A股首次公開發行股票所得款項用途。 | | | | | | 特別決議案 | （註4） 贊成 | （註4） 反對 | （註4） 棄權 | | 2. | 審議及批准修訂公司章程及取消監事會。 | | | | | 3. | 審議及批准修訂本公司股東大會議事規則。 | | | | | 4. | 審議及批准修訂本公司董事會議事規則。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本通告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 上海復旦張江生物醫藥股份有限公司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股票號碼：1349） 於本通告刊發日期，董事會包括以下人士： 作為普通決議案： 1. 審議及批准變更A股首次公開發行股票所得款項用途； 作為特別決議案： 2. 審議及批准修訂公司章程及取消監事會； 3. 審議及批准修訂本公司股東大會議事規則； 4. 審議及批准修訂本公司董事會議事規則。 承董事會命 趙大君 主席 1 臨時股東大會通告 茲通告上海復旦張江生物醫藥股份有限公司（「本公司」謹訂於二零二五年十一月二十六日（星期三）下 午十三時正假座中國上海市浦東新區張江高科技園區蔡倫路308號舉行臨時股東大會（「臨時股東大 會」），以考慮並酌情通過下列決議案。除文義另有所指外，本通告及下列決議案所使用的詞滙與本 公司日期為二零 ...

FF301 第 1 頁 共 11 頁 v 1.1.1 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688505 | 說明 | | A股（上海證券交易所科創板） | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 710,572,100 | RMB | | 0.1 | RMB | | 71,057,210 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 710,572,100 | RMB | | 0.1 | RMB | | 71,057,210 | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | -- ...

Core Viewpoint - The company is changing the use of part of its raised funds from the "Hemoporfin US Registration Project" to the "Photodynamic Drug Innovation R&D Sustainable Development Project" to enhance fund utilization efficiency and focus on advantageous R&D areas [1][8][20]. Summary by Sections 1. Overview of Fundraising Project Change - The original project name was "Hemoporfin US Registration Project," which is now changed to "Photodynamic Drug Innovation R&D Sustainable Development Project" [1]. - The amount of funds redirected is RMB 181.5461 million, which includes interest and investment income as of October 30, 2025 [1][7]. - The new project construction period is from the date of shareholder meeting approval until December 31, 2027 [1][9]. 2. Fundraising Basic Information - The company raised a total of RMB 1.074 billion by issuing 120 million shares at RMB 8.95 per share, with a net amount of RMB 974.3239 million after deducting issuance costs [2]. - The funds have been stored in a dedicated account, ensuring effective supervision [2]. 3. Reasons for Change - The change is due to slower-than-expected clinical research progress influenced by international environments and regulatory policies [8][20]. - The original project will continue as a sub-project under the new project, focusing on the ongoing Phase II clinical research in the US [9][20]. 4. New Project Details - The new project includes various initiatives such as expanding indications for the drug Ameluz, which is used for treating precancerous lesions and other conditions [12][14]. - The company plans to continue developing its photodynamic technology platform, which has shown significant clinical advantages [17][18]. 5. Market Outlook - The company is a leader in the photodynamic drug market, with a strong pipeline and a focus on expanding its product offerings [17][19]. - The photodynamic therapy market is growing due to its unique therapeutic value in treating various conditions [17][18]. 6. Approval Process - The board of directors and the supervisory board have approved the change, which will be submitted for shareholder approval [23][24].